Cerevel Therapeutics Holdings Inc
NASDAQ:CERE

  • LAST PRICE
    42.7500
  • TODAY'S CHANGE (%)
    0.2800 (0.6593%)
  • Bid / Lots
    42.3600/ 1
  • Ask / Lots
    43.0000/ 16
  • Open / Previous Close
    42.4900 / 42.4700
  • Day Range
    42.3800
    42.8450
  • 52 Week Range
    19.5900
    43.5898
  • Volume
    714,167

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Apr 18, 2024

      Show headlines and story abstract

    • 12:17PM ET on Thursday Apr 18, 2024 by Dow Jones
      Companies Mentioned: ABBV, CERE

      By David Wainer

      AbbVies acquisition of neuroscience biotech Cerevel Therapeutics hasnt closed yet. But the latest results from Cerevels Parkinsons disease late-stage trial just made the deal look even better.

    • 9:12AM ET on Thursday Apr 18, 2024 by MT Newswires
      Companies Mentioned: IBB, ELV, XLV, CERE, BHVN
      09:12 AM EDT, 04/18/2024 (MT Newswires) -- Health care stocks were mixed pre-bell Thursday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.4% higher. Elevance Health (ELV) stock was up more tha...

    • 8:35AM ET on Thursday Apr 18, 2024 by MT Newswires
      Companies Mentioned: CERE
      08:35 AM EDT, 04/18/2024 (MT Newswires) -- Cerevel Therapeutics (CERE) said Thursday that a phase 3 study of its investigational drug tavapadon, which is intended for the treatment of Parkinson's disease has met its primary endpoint. The drug candid...

    • 6:30AM ET on Thursday Apr 18, 2024 by GlobeNewswire
      Companies Mentioned: CERE

    • 6:30AM ET on Thursday Apr 18, 2024 by Dow Jones
      Companies Mentioned: CERE

      the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether prior results will be predictive of future results); the impact of COVID-19 and the post-COVID landscape on the timing, progress and results of ongoing or planned clinical trials; our ability to recruit and enroll suitable patients in our clinical trials, including the effectiveness of mitigation measures; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; the ability of the parties to consummate the proposed merger between Cerevel and AbbVie on the timeline anticipated or at all and the possibility that various closing conditions for the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the occurrence of any event, change or other circumstance that could give rise to the termination of the merger; and other risks identified in our SEC filings, including those under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 27, 2024, and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Peers Headlines